Storia in 5 fonti

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Raccontata da

biopharmadive.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo4 h fa

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor…

Capricor stock collapsed 60-70% after FDA briefing documents contradicted the company's May claim that Deramiocel slowed cardiac decline 91% versus placebo. The incident highlights governance risk when clinical trial claims lack pre-specified statistical validation.

originale

Timeline cronologica

lunedì 27 luglio 2026·biopharmadive.com
FDA scientists question Capricor data; Legend CEO steps down
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca…
lunedì 27 luglio 2026·statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Confronto fonti

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor…

Timeline cronologica

FDA scientists question Capricor data; Legend CEO steps down

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

FDA scientists question Capricor data; Legend CEO steps down

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Therapeutics Stock Dives — 'Complete Fraud' Says Martin Shkreli - Capricor Therapeutics (NASDAQ:

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

FDA and Capricor clash over deramiocel efficacy data at Duchenne adcomm vote

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting -…